Tear Sheet

Print Page   Print Page       E-mail Page   Email Page       RSS Feeds   RSS       E-mail Alerts  Email Alerts       Financial Tear Sheet  Tear Sheet

Tear Sheet

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. 

Press Releases
Date Title
05/27/20 Alkermes Highlights New Data From Schizophrenia Portfolio at the American Society of Clinical Psychopharmacology 2020 Annual Meeting
05/20/20 Journal of Clinical Psychiatry Publishes Data from Alkermes' ALPINE Study in Patients With Schizophrenia
05/15/20 Statement from Alkermes on Response to COVID-19
05/14/20 Alkermes Presents New Data From Schizophrenia Portfolio at Virtual 2020 Congress of the Schizophrenia International Research Society
05/11/20 Alkermes Announces Expansion of Patient Services and Provider Network to Support Uninterrupted Access to ARISTADA® and VIVITROL® During COVID-19 Crisis
Stock Quote

Copyright West LLC. Minimum 15 minutes delayed.

SEC Filings

Filing date Description

Filing of certain prospectuses and communications in connection with business combination transactions

Filing of certain prospectuses and communications in connection with business combination transactions

Filing of certain prospectuses and communications in connection with business combination transactions

Filing of certain prospectuses and communications in connection with business combination transactions

Registration of securities issued in business combination transactions